|
|
Post by brotherm1 on May 6, 2020 11:17:51 GMT -5
Well, Afrezza was approved 2014. Why should MNKD expect more interest in technosphere delivery with a trepostinil delivery approval?
|
|
|
|
Post by cedafuntennis on May 6, 2020 12:03:53 GMT -5
Reason is simple. Afrezza has a very limited user base which T has a much larger exposure. If more and more patients start using it and it is successful, visibility and therefore positive acceptance will increase exponentially simply for that reason.
|
|
|
|
Post by mango on May 6, 2020 12:14:24 GMT -5
Reason is simple. Afrezza has a very limited user base which T has a much larger exposure. If more and more patients start using it and it is successful, visibility and therefore positive acceptance will increase exponentially simply for that reason. Pretty soon, tens of thousands of new patients will be using MannKind's inhalers and dry powder. That also means tons of new healthcare providers will be exposed to MannKind's technology and capabilities, as well as, insurances. Increased exposure and further validity are soon coming forth. Cha-ching |
|
|
|
Post by lennymnkd on May 6, 2020 12:46:32 GMT -5
Mango a single thumbs up wasn’t enough; 👍👍👍
|
|
|
|
Post by prcgorman2 on May 6, 2020 12:58:20 GMT -5
www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-remdesivir-global-supply"Gilead is in discussions with some of the world’s leading chemical and pharmaceutical manufacturing companies about their ability, under voluntary licenses, to produce remdesivir for Europe, Asia and the developing world through at least 2022. The company is also negotiating long-term voluntary licenses with several generic drugmakers in India and Pakistan to produce remdesivir for developing countries. Gilead will provide appropriate technology transfers to facilitate this production. Finally, the company is in active discussions with the Medicines Patent Pool, which Gilead has partnered with for many years, to license remdesivir for developing countries. Close coordination of remdesivir manufacturing will be critical. This is why Gilead is working to build a consortium of manufacturing partners – to bring efforts together to help maximize global supply. Producing the drug requires scarce raw materials, with their own lengthy production time, and specialized manufacturing capabilities with limited global capacity. Any disruption to the supply chain impacting these scarce raw materials and other manufacturing inputs could reduce the amount of remdesivir produced and increase the time it takes to do so. " A Hail Mary Good points, but since Remdesivir seems to be most effective if taken early, an inhaled version might turn out to be the most popular form of administration since it could be done without hospitalization and it could be given as soon as a person is diagnosed with COVID-19 versus waiting until they are hospitalized--which wouldn't be "early." Totally agree TS Remdesivir is a "Hail Mary", but if it was as easy and simple to dose and as stable as Afrezza, it could be a very good product for 3rd world and non-hospital administration. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 6, 2020 13:37:36 GMT -5
Well, Afrezza was approved 2014. Why should MNKD expect more interest in technosphere delivery with a trepostinil delivery approval? Because right now Technosphere has only worked on a HORMONE (INSULIN). There is no data nor FDA Approval that TS will work on anything other than a hormone. MNKD needs to prove TS will work on other compounds. UTHR stuck their neck out (an educated and business risk) that Tyvaso could be used on the Technosphere Platform. That's why it's vital TreT is approved. Not only for UTHR's PAH Patients but for MNKD's LIFE. |
|
|
|
Post by lennymnkd on May 6, 2020 13:58:14 GMT -5
I don't think Al Mann would have put "a Billion bucksinto technosphere not knowing it versatility/ and as Matt P said .. an embarrassment of riches!
|
|
|
|
Post by figglebird on Jun 22, 2020 16:05:52 GMT -5
Well, Afrezza was approved 2014. Why should MNKD expect more interest in technosphere delivery with a trepostinil delivery approval? Let me try and re-explain - DPIS ARE BRAND NEW to consumers. Thats why - thats all that matters. Oh and fda approved tech etc. Read up on it. |
|
|
|
Post by agedhippie on Jul 13, 2020 17:25:03 GMT -5
|
|
|
|
Post by peppy on Jul 13, 2020 17:33:37 GMT -5
|
|
|
|
Post by bioexec25 on Jul 13, 2020 18:01:42 GMT -5
Probably an evolution of the small handheld neb they acquired as part of the Corus Pharma acquisition for inhaled tobramycin for the treatment of cystic fibrosis. |
|
|
|
Post by sellhighdrinklow on Jul 13, 2020 20:32:04 GMT -5
I heard on the news today that there is a glass shortage, so making millions of vials for any approved vaccine could prove to be a problem. Sounded odd to me if true.
Another positive for MNKD although admittedly jumping to conclusions of a long shot possibility.
|
|
|
|
Post by prcgorman2 on Jul 14, 2020 6:20:54 GMT -5
Shortages are chronic because of COVID-19.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 14, 2020 6:39:38 GMT -5
|
|
|
|
Post by Chris-C on Jul 14, 2020 15:21:41 GMT -5
Yes. The glass shortage would be a problem, but that concerns me less than the early reports of limited duration immunity. Some reports of re-infections have already occurred. If antibody immunity is shown to be of short duration, I'm not sure how herd immunity (naturally or through vaccination) makes much difference. The way out then becomes the tried and successfully deployed approach of containing the spread through identification, contact tracing, isolation, and quarantine until the virus can find no hosts. But that takes (1) a public health system that works (2) a compliant, responsible community-minded population, and (3) social and economic support systems for people who cannot work while the virus is being contained. To paraphrase Michael Osterholm, we're still in the early innings of this ball game. Stay safe everyone. Chris C |
|
